77th DGU Congress

Urology Connects – Translating Molecular Knowledge into Patient Impact

At this year’s DGU Congress in Hamburg, the theme “Urology connects” highlights the growing importance of molecular insights in personalized cancer care.

Biomarkers such as FGFR3, Nectin-4, HER2 and TROP2 are more than diagnostic readouts, they link research, diagnostics, and targeted therapy. Their integration into clinical practice enables risk-adapted treatment and opens new therapeutic options.

Precision oncology is becoming reality:

In urothelial carcinoma, agents like erdafitinib and enfortumab vedotin demonstrate the impact of biomarker-driven therapies.

In prostate cancer, innovations such as mpMRI and PSMA-targeted approaches, as well as refined biopsy strategies reflect the shift toward individualized, patient-centered care.

As a partner in molecular diagnostics, BIOTYPE supports the translation of biological knowledge into clinical impact by connecting disciplines, technologies, and teams to improve outcomes in urologic oncology.